Free Newsletter
Pfizer, Icagen ink deal
Free newsletter via e-mail
Tools
Pfizer is investing up to $15 million in Icagen as part of a collaboration and licensing agreement covering potential pain meds. The companies will jointly develop drugs that target three sodium ion channels that mediate the nervous system's pain signals. Pfizer is on the hook for all development costs, but it gets exclusive rights to commercialize any products that arise. The deal sent Icagen shares soaring by more than 69 percent to $3.25, in early trading.
- see the release
- here's the report from the Triangle Business Journal
Related Articles:
Troubled Pfizer blueprints biotech venture effort. Report
What's next for Pfizer? Report
WSJ: Pfizer looks at restructuring R&D, new cuts. Report
Troubled Icagen gains $22M in financing. Report
More stories about Pfizer
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
